SK Life Sciences has Licensed Pristima

Share Article

Xybion Medical Systems, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects.

Xybion Medical Systems, a world leader in toxicology and pathology data management solutions and the developer of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

After extensive research and evaluation of the products on the market, SKLSI selected Xybion's Pristima to manage its general toxicology data as well as licensing Xybion's Standard Validation Package and contracting Xybion to perform the full suite of installation, training and validation execution services. Additionally, SKLSI has contracted to have Xybion's professional services team perform all of the hardware installation, third-party software installation and all other IT services related to Pristima.

Dr. Pradip Banerjee, Xybion's CEO, stated that "we are proud to add SK Life Science, Inc., another leading global research and development company to our growing community. We are tremendously satisfied that SKLSI has acknowledged Pristima to be the most powerful system on the market. Pristima is designed to account for all types of toxicology studies and is specifically well-suited to collect, manage and summarize data for global pharmaceutical and chemical companies as well as contract research organizations."

Dr. Hong Wook Kim, Director, Non-clinical Development of SK Life Science, Inc., remarked that "SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects."

About SK Life Sciences - SK Life Science, Inc. (http://pharma.sk.com/english), US subsidiary of SK Holdings, Co., Ltd., one of the largest conglomerate and the leading energy and chemical company in Korea, has been engaged in the innovative discovery and development of novel therapeutic compounds in the field of neuroscience in order to treat CNS disorders including epilepsy, depression, anxiety, schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In addition to the CNS area of research, SK Life Science is working on the discovery and development of novel therapeutic compounds for the treatment of metabolic diseases.

About Xybion Medical Systems - Xybion (http://www.xybion.com) is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to the Pristima Data Management suite, Xybion provides professional services, consulting, training and validation activities to clients throughout the world.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carlos M. Frade
Visit website